![]() |
|
|
Vol. 288, Issue 2, 590-596, February 1999
Unité de Neurobiologie et Pharmacologie Moléculaire
(U.109) de Institut National de la Santé et de la Recherche
Médicale, Paris, France
Clozapine and olanzapine behave as weak H3-receptor
antagonists in vitro with Ki values around 1 and 50 µM, respectively. Despite these modest apparent affinities,
both compounds given orally to mice, nearly doubled steady-state
tele-methylhistamine levels in brain, with
ED50 values as low as 1 and 3 mg/kg, respectively, an
effect comparable to those of potent H3-receptor
antagonists. This effect corresponded to an enhancement of histamine
turnover rate from 45 to 73 ng/g/h as measured in the case of
olanzapine using the pargyline test. Other antipsychotics displaying,
such as clozapine and olanzapine, high 5-hydroxytryptamine
(5-HT)2A receptor antagonist potency, i.e., risperidone,
thioridazine, seroquel, and iloperidone, also enhanced markedly
tele-methylhistamine levels. This effect was 1) additive
with that of a pure H3-receptor antagonist, ciproxifan, 2)
mimicked by a 5-HT2A receptor antagonist, ketanserin, 3)
reversed by a 5-HT2A receptor agonist, DOI, 4) not shared
by antipsychotics with low affinity for the 5-HT2A receptor, i.e., haloperidol, sulpiride, raclopride, or remoxipride that, on the contrary, tended to reduce
tele-methylhistamine levels. We conclude that in
contrast to "typical" antipsychotics, "atypical" antipsychotics
stimulate histamine neuron activity via blockade of the
5-HT2A receptor in vivo. This effect does not appear to account for their reduced extrapyramidal side-effects but may underlie
their pro-cognitive properties.
This article has been cited by other articles:
![]() |
M. J. Millan, F. Loiseau, A. Dekeyne, A. Gobert, G. Flik, T. I. Cremers, J.-M. Rivet, D. Sicard, R. Billiras, and M. Brocco S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1212 - 1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pillot, J. Ortiz, A. Heron, S. Ridray, J.-C. Schwartz, and J.-M. Arrang Ciproxifan, a Histamine H3-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat J. Neurosci., August 15, 2002; 22(16): 7272 - 7280. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Morisset, C. Pilon, J. Tardivel-Lacombe, D. Weinstein, W. Rostene, C. Betancur, P. Sokoloff, J.-C. Schwartz, and J.-M. Arrang Acute and Chronic Effects of Methamphetamine on Tele-Methylhistamine Levels in Mouse Brain: Selective Involvement of the D2 and not D3 Receptor J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 621 - 628. [Abstract] [Full Text] [PDF] |
||||